SpliSense Secures $28.5 Million in Series B Financing
Orbimed, Israel Biotech Fund, Biotel Limited, Integra Holdings and the Cystic Fibrosis Foundation participated in the round.
Uncategorized
Biond Biologics and Sanofi Enter into Global Licensing Agreement for BND-22
Biond to receive $125 million upfront with more than $1 billion in potential development, regulatory, and sales milestones plus royalty payments for global rights to a novel immune checkpoint inhibitor.
Biosight Closes $46M Series C Financing to Advance Clinical Oncology Programs
The round was led by Israel Biotech Fund with participation from new investors, The Phoenix Insurance Company and Migdal Insurance Company, two of Israel’s leading institutional investors, and Biotel, as well as existing investors including Arkin Bio Ventures and Primera Capital.
Biosight Granted U.S. FDA Fast Track Designation for BST-236 for the Treatment of Acute Myeloid Leukemia
BioSight Ltd, a pharmaceutical company developing innovative therapeutics for hematological malignancies and disorders, announced today that the FDA has granted Fast Track designation for BST-236 for the treatment of acute myeloid leukemia (AML).
Biosight Announces Clinical Trial Collaboration with the European Cooperative Group
BioSight Ltd, a pharmaceutical company developing innovative therapeutics for hematological malignancies and disorders, announced today that it has entered into a clinical trial agreement with the European Cooperative Group. The Study is expected to begin in Q4 2020.
Biond Bio appoints Jerome Zeldis, M.D., Ph.D., to Board of Directors
Biond Biologics appoints Jerome Zeldis, M.D., Ph.D., Former Chief Medical Officer of Celgene and a member of Israel Biotech Fund Venture Advisory Team, to its Board of Directors.
Biosight Strengthens Board of Directors with Appointment of Industry Executive, Gary Gordon, M.D, Ph.D.
BioSight Ltd, a pharmaceutical company developing innovative therapeutics for hematological malignancies and disorders, strengthens its Board of Directors with the appointment of Dr. Gary Gordon, an industry executive and a member of Israel Biotech Fund Venture Advisory Team.
Gamida Cell Announces Positive Topline Data from Phase 3 Clinical Study
Gamida Cell (NASDAQ: GMDA), announced positive topline results from its Phase 3 clinical study evaluating the safety and efficacy of omidubicel, an investigational advanced cell therapy in development as a potential life-saving treatment option for patients in need of bone marrow transplant.
Ayala Pharmaceuticals Announces Pricing of Initial Public Offering
Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations, announced the pricing of its initial public offering of 3,666,667 shares of common stock at a public offering price of $15.00 per share.